The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of May 26, 2025. “Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and ...
b Performed 3 months later at the outpatient clinic. c For conversion to mg/dl divide by 0.0555. d For conversion to mg/dl divide by 88.4. a Performed at presentation. b Performed 3 months later ...
The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of May 26, 2025. “Pheochromocytoma and paraganglioma are rare tumors that form in and around the adrenal glands, and ...
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025. The FDA granted priority review to a supplemental new ...
Genes that are as yet unidentified will probably be found to cause hereditary pheochromocytoma or paraganglioma and increase the proportion of hereditary cases above that which has been already ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback